

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Effects of GnRH agonist for luteal support on improvement of intracytoplasmic sperm injection cycles: clinical trial

#### Protocol summary

nazari@sbmu.ac.ir

##### Summary

This study was designed to evaluate the effectiveness of GnRh agonist for luteal support on improvement of intracytoplasmic sperm injection (ICSI) cycles. This clinical trial is performed in Infertility and IVF ward, Taleghani hospital. 240 infertile patients who candidate ICSI with normal ovarian response are recruited into the study in two groups according to randomization method. Subcutaneous injection of 0.1 mg Triptorelin or placebo is performed 6 days after ICSI. Luteal support is performed for all participants as a same protocol (Vaginal Cyclogest 400 mg twice/day). Chemical and clinical pregnancy rate and abortion rate will be analyzed.

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice Chancellor for research of Shahid Beheshti University of Medical Sciences

##### Expected recruitment start date

2016-04-20, 1395/02/01

##### Expected recruitment end date

2017-04-21, 1396/02/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2016101729027N2**

Registration date: **2016-10-24, 1395/08/03**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2016-10-24, 1395/08/03

##### Registrant information

###### Name

Leila Nazari

###### Name of organization / entity

Shahid Beheshti University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 2271 8000

###### Email address

##### Scientific title

Effects of GnRH agonist for luteal support on improvement of intracytoplasmic sperm injection cycles: clinical trial

##### Public title

Effects of GnRH agonist for luteal support on improvement of intracytoplasmic sperm injection cycles

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Age between 20-38; Body mass index (BMI) between 20-30; fresh embryo transfer cycles; 3rd menstrual day serum FSH below 10; absence of low ovarian response according Bologna Criteria Exclusion criteria: unwillingness to continue; absence of good quality embryo; ovarian hyper stimulation (more than 18 mature follicle during ovarian stimulation)

##### Age

From **20 years** old to **38 years** old

##### Gender

Female

## Phase

2-3

## Groups that have been masked

No information

## Sample size

Target sample size: **240**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shahid Beheshti University of  
Medical Sciences

##### Street address

Velenjak, Yaman St, Chamran highway

##### City

Tehran

##### Postal code

#### Approval date

2016-05-28, 1395/03/08

#### Ethics committee reference number

IR.SBMU.MSP.REC.1395.65

## Health conditions studied

### 1

#### Description of health condition studied

Noninflammatory disorders of female genital tract

#### ICD-10 code

N98.9

#### ICD-10 code description

Complication associated with artificial fertilization,  
unspecified

## Primary outcomes

### 1

#### Description

Clinical pregnancy

#### Timepoint

4 weeks after embryo transfer

#### Method of measurement

Transvaginal ultrasound

### 2

#### Description

Chemical pregnancy

#### Timepoint

2 weeks after embryo transfer

#### Method of measurement

Serum BHCG

## Secondary outcomes

### 1

#### Description

Ongoing pregnancy

#### Timepoint

10 weeks after embryo transfer

#### Method of measurement

Fetal heart beat in ultrasound

### 2

#### Description

Abortion

#### Timepoint

Before 20 weeks of pregnancy

#### Method of measurement

Fetal demise before 20 weeks of gestation

## Intervention groups

### 1

#### Description

Intervention group: Subcutaneous injection of Triptorelin  
(0.1 mg) 6 days after ICSI

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Subcutaneous injection of placebo 6 days  
after ICSI

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Infertility and IVF ward of Talghani hospital

##### Full name of responsible person

Leila Nazari

##### Street address

Yaman St, Velenjak, Chamran highway

##### City

Tehran

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**

Vice Chancellor for research of Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Afshin Zarghi

**Street address**

Shahid Beheshti University of Medical Sciences, Yaman st, Velenjak, Chamran highway

**City**

Tehran

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice Chancellor for research of Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Leila Nazari

**Position**

Assistant professor

**Other areas of specialty/work****Street address**

Taleghani hospital, Yaman st, Velenjak, Chamran highway

**City**

Tehran

**Postal code****Phone**

+98 21 2243 2558

**Fax****Email**

nazari@sbmu.ac.ir

**Web page address**

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Nasrin Saharkhiz

**Position**

Associated professor

**Other areas of specialty/work****Street address**

Taleghani hospital, Yaman st, Velenjak, Chamran highway

**City**

Tehran

**Postal code****Phone**

+98 21 2243 2558

**Fax****Email**

saharkhiz1377@yahoo.com

**Web page address**

## Person responsible for updating data

**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Leila Nazari

**Position**

Assistant professor

**Other areas of specialty/work****Street address**

Taleghani hospital, Yaman st, Velenjak, Chamran highway

**City**

Tehran

**Postal code****Phone**

+98 21 2243 2558

**Fax****Email**

nazari@sbmu.ac.ir

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*